Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use - Non-Executive Director Joe Ciaffoni buys 56,000 shares at USD8.96, worth USD501,519, on Thursday. Indivior on Thursday named Ciaffoni as its next chief executive officer, replacing Mark Crossley. The handover is expected to be after Indivior's annual general meeting in May. Indivior said Crossley is stepping down "by mutual agreement" and "following a distinguished tenure" as CEO since 2020. Crossley joined the board in December, and the 56,000 shares are his first holding. Most recently, he was CEO of Nasdaq-listed Collegium Pharmaceutical Inc.
Ciaffoni is joined in buying Indivior shares on Thursday by Chair David Wheadon and non-executive directors Robert Schriesheim and Daniel Ninivaggi, who buy 10,000, 58,833 and 15,000 shares, respectively.
Current stock price: 675.50p, down 3.5% in London on Friday
12-month change: down 61%
By Tom Waite, Alliance News editor
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.